Nautilus regains Nasdaq minimum bid price compliance; deficiency closed

Nautilus Biotechnology, Inc.

Received notice on Nov 3, 2025 that closing bid price met $1 for 10 consecutive days.
Deficiency previously disclosed May 2, 2025; compliance period extended to April 27, 2026.
Company transferred to Nasdaq Capital Market on Oct 29, 2025 to utilize second compliance period.
Matter now closed; no further action required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.